Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Mantle Cell Lymphoma
Related studies linked through entity extraction aliases.
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse
- Status
- TERMINATED
- Phase
- PHASE2
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
- Status
- COMPLETED
- Phase
- N/A
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- Status
- COMPLETED
- Phase
- PHASE1
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
- Status
- COMPLETED
- Phase
- PHASE2
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
- Status
- COMPLETED
- Phase
- PHASE4